Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:
Switzerland
Page logo

Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes
Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

New Brunswick, NJ (June 5, 2012) – Janssen and Johnson & Johnson will provide investors and other interested parties an overview presentation of results from five pivotal Phase 3 studies evaluating investigational canagliflozin for the treatment of Type 2 Diabetes on Sunday, June 10 at approximately 2:00 p.m., Eastern Time. These data will be presented at the American Diabetes Association annual meeting in Philadelphia, Pa.

The presentation can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on “Webcasts/Presentations.”

###

Press Contacts:
Al Wasilewski
(732) 524-1130

Bill Price
(732) 524-6623

Investor Contacts:
Stan Panasewicz
(732) 524-2524

Louise Mehrotra
(732) 524-6491

Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue